Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

PET imaging cancer stem cells using a novel zirconium-89 labelled fully human anti-CD133 antibody

Kevin Wyszatko, John Valliant, Saman Sadeghi and Sheila Singh
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 154;
Kevin Wyszatko
1McMaster University Hamilton ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Valliant
1McMaster University Hamilton ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saman Sadeghi
1McMaster University Hamilton ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheila Singh
1McMaster University Hamilton ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Information

vol. 62 no. supplement 1 154

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 18, 2021.

Copyright & Usage 
© 2021

Author Information

  1. Kevin Wyszatko1,
  2. John Valliant1,
  3. Saman Sadeghi1 and
  4. Sheila Singh1
  1. 1McMaster University Hamilton ON Canada

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2021 to April 2025

AbstractFullPdf
May 20212400
Jun 20214400
Jul 20212300
Aug 20212100
Sep 20212700
Oct 20212600
Nov 20212500
Dec 20213100
Jan 20222100
Feb 20222900
Mar 20225700
Apr 20225100
May 20221100
Jun 20221900
Jul 20221100
Aug 20223000
Sep 20222100
Oct 20221300
Nov 20222000
Dec 20221600
Jan 20231600
Feb 20231400
Mar 20231600
Apr 2023700
May 20231100
Jun 2023900
Jul 2023600
Aug 20231100
Sep 20231000
Oct 20232400
Nov 20231400
Dec 20232400
Jan 20242900
Feb 20241100
Mar 20241800
Apr 20243000
May 20242200
Jun 20243200
Jul 20247400
Aug 20246600
Sep 20242700
Oct 20244900
Nov 20245000
Dec 20243900
Jan 20253200
Feb 20253900
Mar 20253500
Apr 20255800
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET imaging cancer stem cells using a novel zirconium-89 labelled fully human anti-CD133 antibody
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET imaging cancer stem cells using a novel zirconium-89 labelled fully human anti-CD133 antibody
Kevin Wyszatko, John Valliant, Saman Sadeghi, Sheila Singh
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 154;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET imaging cancer stem cells using a novel zirconium-89 labelled fully human anti-CD133 antibody
Kevin Wyszatko, John Valliant, Saman Sadeghi, Sheila Singh
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 154;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma
  • Using an assumed lung mass underestimates the lung absorbed dose in patients undergoing 90Y radioembolization therapy
  • Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
Show more Oral - PhysicianPharm

High Impact Radiochemistry: Techniques, Tracers, and Targets

  • Radiosynthesis and Evaluation of [11C]HC070, a Promising PET Tracer for Imaging Transient Receptor Potential Canonical 5 (TRPC5)
  • PET imaging of c-Met activity in NSCLC using 18F Labelled c-MET inhibitor
  • Assessment of Ultrasmall Nanocluster for Early and Accurate Detection of Atherosclerosis Using Positron Emission Tomography/Computed Tomography
Show more High Impact Radiochemistry: Techniques, Tracers, and Targets

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire